Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)

Mark C Gillies¹, Vincent Daien², Vuong Nguyen¹, Daniel Barthelmes³

Affiliations

¹ The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
² The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.
³ The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

PMID: 28219517
DOI: 10.1016/j.ophtha.2016.05.054

Comment

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)

Mark C Gillies et al. Ophthalmology. 2017 Mar.

. 2017 Mar;124(3):e31-e32.

doi: 10.1016/j.ophtha.2016.05.054.

Authors

Mark C Gillies¹, Vincent Daien², Vuong Nguyen¹, Daniel Barthelmes³

Affiliations

¹ The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
² The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.
³ The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

PMID: 28219517
DOI: 10.1016/j.ophtha.2016.05.054

Erratum in

Corrigendum.
[No authors listed] [No authors listed] Ophthalmology. 2017 May;124(5):746. doi: 10.1016/j.ophtha.2017.03.001. Ophthalmology. 2017. PMID: 28433131 No abstract available.

No abstract available

PubMed Disclaimer

Comment in

Reply.
Maguire MG; CATT Research Group. Maguire MG, et al. Ophthalmology. 2017 Mar;124(3):e33. doi: 10.1016/j.ophtha.2016.06.046. Ophthalmology. 2017. PMID: 28219518 No abstract available.

Comment on

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2016 Aug;123(8):1751-1761. doi: 10.1016/j.ophtha.2016.03.045. Epub 2016 May 2. Ophthalmology. 2016. PMID: 27156698 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Erratum in

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources